503 related articles for article (PubMed ID: 16240706)
1. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
2. Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion.
Midha KK; Rawson MJ; McKay G; Hubbard JW
Int J Clin Pharmacol Ther; 2005 May; 43(5):244-54. PubMed ID: 15906590
[TBL] [Abstract][Full Text] [Related]
3. Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
Endrenyi L; Tothfalusi L
J Pharm Pharm Sci; 2009; 12(1):138-49. PubMed ID: 19470298
[TBL] [Abstract][Full Text] [Related]
4. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
5. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the bioequivalence of highly-variable drugs and drug products.
Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
[TBL] [Abstract][Full Text] [Related]
7. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
Lechat P
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence approaches for highly variable drugs and drug products.
Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
[TBL] [Abstract][Full Text] [Related]
10. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).
Tothfalusi L; Endrenyi L; Midha KK
Int J Clin Pharmacol Ther; 2003 May; 41(5):217-25. PubMed ID: 12776813
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
Tothfalusi L; Endrenyi L; Arieta AG
Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
[TBL] [Abstract][Full Text] [Related]
12. Prescribability and switchability of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
[TBL] [Abstract][Full Text] [Related]
13. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs.
Boddy AW; Snikeris FC; Kringle RO; Wei GC; Oppermann JA; Midha KK
Pharm Res; 1995 Dec; 12(12):1865-8. PubMed ID: 8786957
[TBL] [Abstract][Full Text] [Related]
14. Limits for the scaled average bioequivalence of highly variable drugs and drug products.
Tothfalusi L; Endrenyi L
Pharm Res; 2003 Mar; 20(3):382-9. PubMed ID: 12669957
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence: switchability and scaling.
Midha KK; Rawson MJ; Hubbard JW
Eur J Pharm Sci; 1998 Apr; 6(2):87-91. PubMed ID: 9795020
[TBL] [Abstract][Full Text] [Related]
18. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
[TBL] [Abstract][Full Text] [Related]
19. Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?
Hauck WW; Parekh A; Lesko LJ; Chen ML; Williams RL
Int J Clin Pharmacol Ther; 2001 Aug; 39(8):350-5. PubMed ID: 11515710
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a scaling approach for the bioequivalence of highly variable drugs.
Haidar SH; Makhlouf F; Schuirmann DJ; Hyslop T; Davit B; Conner D; Yu LX
AAPS J; 2008 Sep; 10(3):450-4. PubMed ID: 18726698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
